Indaptus Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Indaptus Therapeutics, Inc. (INDP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 85.35 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-13
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 72.07K shares, a 6311.65% increase year-over-year.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 13.28K shares, a 2025.44% increase year-over-year.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 5.49K shares.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 270.00 shares.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 7.51K shares, a 1101.28% increase from fiscal 2024.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 625.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 72.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 85.35K shares 10-Q · filed 2026-08-13 | 90.84K shares derived: sum of 3 quarters · filed 2026-08-13 | 91.11K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 13.28K shares 10-Q · filed 2026-05-15 | 18.77K shares derived: sum of 2 quarters · filed 2026-05-15 | 19.04K shares derived: sum of 3 quarters · filed 2026-05-15 | 20.17K shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | 5.49K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 5.76K shares derived: sum of 2 quarters · filed 2026-03-17 | 6.88K shares derived: sum of 3 quarters · filed 2026-03-17 | 7.51K shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 270.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 1.39K shares derived: sum of 2 quarters · filed 2025-11-12 | 2.02K shares 10-Q · filed 2025-11-12 | 2.02K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 1.12K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 1.75K shares 10-Q · filed 2025-08-13 | 1.75K shares derived: sum of 3 quarters · filed 2025-08-13 | |
| 2025-03-31 | 625.00 shares 10-Q · filed 2025-05-14 | 625.00 shares derived: sum of 2 quarters · filed 2025-05-14 | ||
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 625.00 shares 10-K · filed 2025-03-13 | ||
| 2024-09-30 | 625.00 shares 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |